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BACKGROUND: The combination of chemotherapy with the vascular endothelial growth factor (VEGF) antibody bevacizumab is a
standard of care in advanced colorectal cancer (CRC). However, biomarkers predicting outcome of bevacizumab-containing
treatment are lacking. As angiopoietin-2 (Ang-2) is a key regulator of vascular remodelling in concert with VEGF, we investigated its
role as a biomarker in metastatic CRC.
METHODS: Serum Ang-2 levels were measured in 33 healthy volunteers and 90 patients with CRC. Of these, 34 had metastatic disease
and received bevacizumab-containing therapy. To determine the tissue of origin of Ang-2, quantitative real-time PCR was performed
on microdissected cryosections of human CRC and in a murine xenograft model of CRC using species-specific amplification.
RESULTS: Ang-2 originated from the stromal compartment of CRC tissues. Serum Ang-2 levels were significantly elevated in patients
with metastatic CRC compared with healthy controls. Amongst patients receiving bevacizumab-containing treatment, low
pre-therapeutic serum Ang-2 levels were associated with a significant better response rate (82 vs 31%; Po0.01), a prolonged median
progression-free survival (14.1 vs 8.5 months; Po0.01) and a reduction of 91% in the hazard of death (Po0.05).
CONCLUSION: Serum Ang-2 is a candidate biomarker for outcome of patients with metastatic CRC treated with bevacizumab-
containing therapy, and it should be further validated to customise combined chemotherapeutic and anti-angiogenic treatment.
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The overall survival (OS) time of patients with metastatic
colorectal cancer (CRC) has increased owing to novel therapeutic
strategies combining chemotherapy with monoclonal antibodies
against vascular endothelial growth factor (VEGF) or epidermal
growth factor receptor (EGFR). Whereas mutations in the k-ras
oncogene predict outcome to EGFR antibody treatment in patients
with metastatic CRC (Lievre et al, 2006; Karapetis et al, 2008),
equivalent biomarkers for the VEGF antibody, bevacizumab, are
currently lacking (Jubb et al, 2006b; Sessa et al, 2008), mainly
because the specific molecular determinants of clinical response
and resistance to the drug are unknown. Similarly, there are
currently no established biomarkers predicting outcome to
chemotherapy in CRC (De Roock et al, 2009).
Originally, it was anticipated that traditional markers of tumour
angiogenesis would predict outcome to bevacizumab. However,
neither VEGF expression levels nor tumour microvessel density
(MVD) were found to be predictive of treatment response, disease
progression or death in CRC patients receiving chemotherapy plus
the antibody (Jubb et al, 2006a). Newer studies evaluated alternative
surrogates of neovascularisation such as circulating endothelial cells
and phosphorylated VEGF receptor in cancers other than CRC
(Murukesh et al, 2010). Results were promising, but assay
requirements prevent widespread application in larger trials.
The therapeutic blockade of VEGF by bevacizumab in CRC
patients induces complex changes in the stromal compartment of
the tumour lesion, including the loss of chaotic microvessels,
remodelling of the vascular wall and a reduction in the interstitial
fluid pressure (Willett et al, 2004). Such stromal alterations are
part of the vascular ‘normalisation’ process induced by bevacizu-
mab and contribute to more efficient delivery of chemo-
therapeutic agents (Jain, 2005; Jain et al, 2006). Recently, dynamic
Revised 26 July 2010; accepted 2 September 2010; published online 5
October 2010
*Correspondence: Dr UT Hacker; E-mail: ulrich.hacker@uni-koeln.de
8These authors contributed equally to this work.
British Journal of Cancer (2010) 103, 1407–1414
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
scontrast-enhanced magnetic resonance imaging was proposed to
assess the extent of vascular normalisation and predict clinical
outcome to VEGF-targeting treatment (Sorensen et al, 2009;
Murukesh et al, 2010). However, molecular markers reflecting the
normalisation status of the tumour vascular bed as part of the
tumour stroma have not been explored in this regard so far.
The molecular alterations of tumour cells are traditionally
regarded as the major determinants of clinical response to
chemotherapy. However, the above observations suggest that the
vascular microenvironment of tumour cells could be equally
important for efficacious cytostatic treatment. Surrogates of
vascular normalisation, therefore, might predict outcome to
chemotherapy as well as to VEGF-targeting therapy.
Angiopoietin-2 (Ang-2) is an inhibitory ligand of the Tie-2
receptor that is stored in the Weibel–Palade bodies of endothelial
cells (Fiedler et al, 2004) and disrupts the integrity of the blood
vessel wall, thus counteracting vascular normalisation (Maison-
pierre et al, 1997; Scharpfenecker et al, 2005; Falcon et al, 2009;
Reiss et al, 2009). On the basis of this, we expected Ang-2 to be
predominantly expressed in the stromal compartment of CRC, and
hypothesised that low and high serum Ang-2 levels in patients with
metastatic CRC would predict different outcomes to bevacizumab-
containing treatment.
MATERIALS AND METHODS
Microdissection
For microdissection analysis, cyrosections were prepared from
human adenocarcinoma samples. Discrete areas of tumour or
stromal tissue were microdissected using a laser microbeam
(P.A.L.M., Bernried, Germany). Microdissected tissue areas (each
100mm in diameter, 30 per slide for stroma and tumour each) were
laser catapulted into a microfuge tube.
Xenografts
Animal experiments were performed in accordance with the
German animal protection law. The colon carcinoma cell line
LS174T was purchased from ATCC (Manassas, VA, USA) to
establish xenografts in nude mice. Cultured LS174T cells (5 10
6)
were injected subcutaneously into the flank region of male
BALB/cA nude mice (Taconic, Ry, Denmark). Animals were killed
after tumour size had reached 10mm in diameter.
Cell cultures
The colon carcinoma cell lines LS174T, HT29, DLD-1 and SW948
were cultured in VLE RPMI 1640 (Biochrom, Berlin, Germany)
supplemented with 10% FCS. Human umbilical vein endothelial
cells were purchased from Promocell (Heidelberg, Germany)
and cultured in endothelial cell growth medium (Promocell). All
cell lines were maintained at 371C and 5% CO2, except for one
experiment involving exposure to controlled hypoxia (1% O2,
5% CO2, balanced N2) for 24h.
Quantitative real-time PCR
The RNA was extracted from tissue microdissections using the
NucleoSpin RNA isolation kit (Macherey-Nagel, Du ¨ren, Germany)
and reverse transcribed using the RevertAid cDNA Synthesis Kit
(Fermentas, St Leon-Rot, Germany). For gene expression analysis
in xenografts, tumours were suspended in RNAlater (Qiagen,
Hilden, Germany). The RNA was extracted as described above.
Real-time PCR for Ang-2 was carried out using the LightCycler
FastStart DNA Master Plus Mix (Roche, Basel, Switzerland).
Results were normalised to a dilution series of pre-quantified
pooled PCR products with the RelQuant Software (Roche). Primer
sequences for human- and murine-specific amplification of Ang-2
and b-actin were as published (Thijssen et al, 2004). Universal
GAPDH primers were as follows: Forward 50-TGC(A/C)TCCTGC
ACCACCAACT-30, Reverse 50(C/T)GCCTGCTTCACCACCTTC-30.
Western blot
For western blot (WB) analysis, cytosolic extracts of cultured cells
were prepared as described previously (Kashkar et al, 2002). Equal
amounts (100mg) of protein were separated by SDS-PAGE,
transferred to a nitrocellulose membrane (Schleicher & Schuell,
Dassel, Germany), and probed with Ang-2 antibody (F18, Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Primary antibodies
were detected using a horseradish-peroxidase-conjugated second-
ary antibody (1:2000; Dako, Hamburg, Germany) and visualised
with the ECL system (Amersham Biosciences, Hamburg,
Germany). Culture supernatants were analysed for Ang-2 protein
concentrations using Quantikine Immunoassays (R&D Systems,
Wiesbaden, Germany).
Clinical samples
A total of 90 patients with colorectal adenocarcinoma and 33
healthy volunteers were studied between September 2005 and
November 2008. One cohort of 56 patients had newly diagnosed
CRC of various stages (UICC I–IV). After obtaining informed
consent, serum samples and tumour tissues were collected at the
time of primary resection (sampling from September 2005 to
August 2006). A second cohort of 34 patients had primary (n¼25)
or relapsed (n¼9) CRC of advanced stage and received a
combination treatment of bevacizumab and chemotherapy either
in the context of a clinical trial (AIO trial KRK 0604, n¼15)
conducted by the Department of Internal Medicine of the
University Hospital Bochum (Reinacher-Schick et al, 2008) or
without participating in a clinical trial (n¼19) at the Center of
Integrated Oncology Cologne-Bonn. Following approval by the
Ethics Committees, serum samples from these patients were taken
prior to treatment (sampling from March 2006 to April 2008).
Where available, paraffin blocks of tumour tissue were retrieved
from the local pathology archives.
Demographical, clinical and histopathological baseline para-
meters were documented in all patients. For patients receiving
bevacizumab-containing therapy, the clinical response after
2 months of treatment was assessed according to response
evaluation criteria in solid tumours (RECIST). Patients were
continuously monitored during the course of treatment and
disease progression and deaths occurring during and after therapy
were recorded.
Enzyme-linked immunosorbent assay
Quantikine Immunoassays (R&D Systems) were used to measure
protein concentrations of Ang-2 and VEGF in serum samples
according to the manufacturer’s instructions.
Immunohistochemistry
Sections of paraffin tissue blocks of CRC specimens were
processed for histological analysis as previously described
(Eberhard et al, 2000). Immunohistochemistry (IHC) for Ang-2
was carried out with the following antibodies: MAB 0983 (R&D
Systems), N18 and F18 (Santa Cruz Biotechnology). To assess non-
specific antibody binding, Ang-2 antibodies were blocked by pre-
incubation with recombinant Ang-2 (ratio 1:5, R&D systems)
prior to incubation of histological sections. A biotinylated
secondary antibody, streptavidin peroxidase complex, and diami-
nobenzidine as the substrate (Zymed, Carlsbad, CA, USA) were
used to visualise binding of the primary antibody (followed by
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ssemiquantitative assessment of Ang-2 staining intensity). Tumour
blood vessels were stained with the CD34 antibody QBEnd/10
(Novocastra Laboratories, Wetzlar, Germany) and the a-SMA
antibody 1A4 (Dako). Microvessel density and pericyte coverage
(PC) were assessed as described previously (Eberhard et al, 2000).
Statistical analysis
The SPSS 17 software (SPSS Inc., Chicago, IL, USA) was used for
data analysis. Areas under receiver operating characteristic curves
(AUROCs) were measured to assess the diagnostic performance of
continuous test variables for treatment response as the target
variable. Youden’s index was calculated to determine cutoff values
of test variables. Parameters others than survival were compared
using the Mann–Whitney test and the w
2-test. Overall and
progression-free survival (PFS) was calculated using the Kaplan–
Meier method. The log-rank test was used to compare survival
time periods between groups. A Cox regression model was applied
for univariate and multivariate analysis to estimate hazard ratios.
All statistical tests were two sided. Statistical significance was
defined as Po0.05. Data analysis is reported according to
REMARK guidelines (Mallett et al, 2010).
RESULTS
Ang-2 is expressed in the stromal compartment of
CRC but not in the tumour cells
Extensive immunohistochemical analysis of Ang-2 with three
frequently reported commercial Ang-2 antibodies produced
ambiguous results concerning the tissue localisation in human
CRC because of poor antibody specificity (Supplementary
Figure 1). Therefore, to identify the tissue of origin of Ang-2 in
CRC, laser-captured microdissection was used to isolate the
tumour and stromal compartments from tissue sections of CRC
patients for quantitative real-time PCR (Figure 1A). The Ang-2
mRNA was clearly detectable in the dissected stromal compart-
ment, but not in the tumour cell compartment (Figure 1B).
Xenografts of CRC in nude mice were generated to further verify
the stromal origin of Ang-2. In these animals, the stromal
compartment is of murine origin and the tumour cell compart-
ment is of human origin (LS174T colon carcinoma cells). Using
species-specific RT–PCR, Ang-2 mRNA expression was found to
be exclusively of stromal (murine) origin (Figure 1C). Correspond-
ingly, no significant amount of Ang-2 protein was detectable in
cytosolic extracts and culture supernatants of various colon
carcinoma cell lines (LS174T, HT29, DLD-1 and SW948) cultured
under normoxia or hypoxia to mimic the conditions inside the
tumour (Supplementary Figure 2).
Serum Ang-2 levels are elevated in CRC patients with
metastatic disease
Blood serum concentrations of Ang-2 were studied in a total of 90
patients with colorectal adenocarcinoma and 33 healthy volun-
teers. The patient demographics are summarised in Table 1. In
UICC stage IV patients, serum Ang-2 levels were significantly
higher compared with patients with UICC stage I–III or healthy
controls (3.9 vs 2.3ngml
 1, P¼0.001 and 3.9 vs 2.4ngml
 1,
P¼0.006, respectively) (Figure 2). In contrast, serum Ang-2 levels
did not differ significantly between UICC stage I–III patients and
controls.
Serum Ang-2 levels identify CRC patients of different
clinical outcomes to bevacizumab-containing therapy
On enrolment, 34 patients with primary or relapsed CRC of UICC
stage IV were treated with bevacizumab in combination with
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Figure 1 Expression of Ang-2 in CRC. (A) Illustration of the steps
involved in laser microdissection of cryosections of CRC patients to obtain
stromal (S) and tumour (T) material for RT–PCR amplification. The top
row shows capture of tumour and the bottom row capture of stroma
from the same section. (B) Gel electrophoresis of end point RT–PCR
amplification products of Ang-2 and b-actin on material of a whole tumour
section (W) or microdissected stromal or tumour areas of sections of five
different CRC patients showing Ang-2 expression in W and S, but not in T.
b-Actin served as a control. The bar chart shows the relative quantitative
real-time PCR of Ang-2 levels normalised to b-actin expression using
the DCt method. Bars represent the means of five patients with standard
errors showing significant Ang-2 expression (100%) in the tumour stroma,
but undetectable in the tumour cells themselves (*). Some expression
(o10%) is also seen when whole sections were amplified, owing to the
Ang-2 expressing stromal compartment. (C) End point RT–PCR analysis
of xenograft tumours of human LS174T cells in nude mice analysed by
species-specific amplification for human (tumour) and murine (stromal)
Ang-2. Xenograft tumours show stromal-derived murine Ang-2, but not
tumour-derived human Ang-2. The GAPDH was used as a species
independent control. Human umbilical vein endothelial cells (HUVEC)
served as a positive control for human Ang-2.
Serum angiopoietin-2 in colorectal cancer
V Goede et al
1409
British Journal of Cancer (2010) 103(9), 1407–1414 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
schemotherapy and followed for clinical outcome. Individual
patient characteristics and outcomes are presented in Table 2.
A total of 19 patients responded to treatment, whereas the rest had
stable or progressive disease. The overall PFS was 12.1 months.
After a median follow-up period of 16.6 months (range 4–26), the
median OS had not been reached. No significant differences in
survival times and response rates were found between different
study sites, gender or age groups (Supplementary Table 1).
Pre-therapeutic serum Ang-2 concentrations in CRC patients
ranged from 0.7 to 12.1ngml
 1 (median: 3.5ngml
 1) and did
not correlate with other vascular markers such as serum levels of
VEGF (median: 0.19ngml
 1), tumour MVD (median: 42 per HPF)
or PC (median: 52%). Measured serum Ang-2 and VEGF levels
were unbiased by gender, age, ECOG status, treatment line or
regimen and showed no correlation with the numbers of metastatic
sites (Supplementary Table 2).
The AUROC was 0.77 for serum Ang-2 (95% CI: 0.61–0.94;
P¼0.008) when using treatment response as the outcome
parameter. The AUROC for tumour MVD was 0.81, but statistical
significance was marginal (95% CI: 0.53–1.00; P¼0.03). For serum
VEGF and PC, AUROC did not differ significantly from 0.50. Based
on ROC analysis and Youden’s index, a serum Ang-2 of 3.5ngml
 1
was chosen as the cutoff value and patients were dichotomised
into subgroups with low or high serum Ang-2 concentrations.
Significantly more patients with low serum Ang-2 levels responded
to treatment than patients with high serum Ang-2. The overall
response rate (OR) in the two groups was 82 and 31% (P¼0.005),
respectively (Figure 3A). Mean serum Ang-2 concentrations were
lower in treatment responders compared with non-responders
(3.3 vs 5.8ngml
 1; P¼0.008). Disease control was significantly
better in patients with low serum Ang-2 levels than in patients with
high serum Ang-2 (median PFS: 14.1 vs 8.5 months; P¼0.009)
(Figure 3B). There was a 63% reduction in the hazard of
progression for patients with low serum Ang-2 compared with
those with high serum Ang-2 (HR 0.37; 95% CI: 0.17–0.80;
P¼0.01). Overall survival was remarkably prolonged in patients
with low serum Ang-2 levels (median OS: not reached) compared
with the group of patients with high serum Ang-2 (median OS: 16.2
months; P¼0.004). Survival rates at 1.5 years were 94 versus 53%
in the low and high serum Ang-2 group, respectively (Figure 3C),
and the hazard of death in low Ang-2 patients was reduced by 91%
compared with patients with high serum Ang-2 levels (HR 0.09;
95% CI: 0.01–0.70; P¼0.02). Differences in survival remained
significant when patients with primary and relapsed CRC were
analysed separately (Supplementary Table 3), and in a multivariate
analysis of variables with potential impact on OR, PFS and OS
(gender, age, site, treatment regimen and treatment line), serum
Ang-2 was confirmed as an independent prognostic marker for all
three end points (P¼0.003, P¼0.005 and P¼0.003, respectively).
In contrast to serum Ang-2 levels, there was no significant
association between OR, PFS or OS and low vs high serum VEGF
or tumour PC, respectively, using cutoff values as determined
by ROC analysis and Youden’s index. Similarly, tumour MVD
was not associated with these end points except for OR (Table 2,
Figure 4).
DISCUSSION
Bevacizumab is a VEGF-targeting antibody that is widely used in
combination with chemotherapy to treat metastatic CRC (Cercek
and Saltz, 2008; McCormack and Keam, 2008). Although much has
been learned about its mechanisms of action, suitable biomarkers
predicting patients who are likely to benefit from bevacizumab
treatment remain elusive (Jubb et al, 2006b; Sessa et al, 2008;
Murukesh et al, 2010). Expression levels of VEGF, in particular,
are not predictive of outcome in CRC patients treated with
bevacizumab (Jubb et al, 2006a). So far, the search for outcome
predictors in CRC has failed for bevacizumab and antibody-free
chemotherapeutic regimens alike (De Roock et al, 2009).
Although VEGF is primarily produced by tumour cells, its target
structure is the tumour vasculature embedded in the stromal
compartment, where the therapeutic effects of the antibody involve
extensive changes such as blood vessel pruning and reorganisation
of the chaotic tumour vasculature (Willett et al, 2004). Thus,
stromal factors controlling the responsiveness of blood vessels to
VEGF withdrawal rather than determinants of VEGF availability
are attractive candidates as outcome predictors for bevacizumab
treatment. Potentially, stromal factors are also outcome
predictors of chemotherapy, because the delivery of cytostatic
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Figure 2 Serum levels of Ang-2 in CRC (n¼90). Serum Ang-2 in
healthy controls, non-metastatic (stage I–III) and metastatic disease
(stage IV). Ang-2, angiopoietin-2.
Table 1 Demographics of studied patients
N (%)
Patients 90 (100.0)
Sex
Male 54 (60.0)
Female 36 (40.0)
Age
Median (years) 69
Range (years) 45–86
o65 years 31 (34.4)
X65 years 59 (65.6)
Stage (UICC)
a
I 3 (3.3)
II 30 (33.3)
III 15 (16.7)
IV 42 (46.7)
Systemic therapy
Unfollowed
b 56 (62.2)
Followed
c 34 (37.8)
Controls 33
Abbreviations: BV¼bevacizumab; CRC¼colorectal cancer; UICC¼Union for
International Cancer Control.
aAt enrolment.
bPatients with primary CRC who
underwent tumour resection and were not followed up for outcome of any further
treatment.
cPatients with primary or relapsed CRC who received BV-containing
therapy and were followed up for treatment outcome.
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sdrugs to tumour cells is controlled by the vascular tumour
microenvironment.
Angiopoietin-2 has been proposed as a gatekeeper of VEGF
function and vascular remodelling. (Hanahan, 1997; Augustin et al,
2009). We here identified Ang-2 as a stromal factor in CRC. In
tumour lesions of CRC patients and in a murine xenograft model
of CRC, Ang-2 mRNA was expressed exclusively in the tumour
stromal compartment, but not in the tumour cell compartment
itself. Although these findings are at odds with previous
immunohistochemical studies reporting Ang-2 expression in the
tumour cell compartment of CRC (Ochiumi et al, 2004; Ogawa
et al, 2004; Chung et al, 2006; Gu et al, 2006), the published
immunohistochemical data should be interpreted with caution
owing to the limited specificity of the available antibodies. Indeed,
careful analysis of the tissue localisation of Ang-2 expression in
cancer entities and tumour models other than CRC has called into
question the tumour cell origin of Ang-2 (Zhang et al, 2003).
To further elucidate the clinical impact of stromal-derived
Ang-2, we measured serum Ang-2 concentrations in CRC patients.
Serum Ang-2 levels were significantly elevated in patients with
metastatic disease. Indeed, Ang-2 has been shown to promote
metastatic growth (Imanishi et al, 2007). Although one can only
speculate as to what extent the stromal expression of Ang-2
contributes to serum Ang-2 concentrations in patients with
advanced CRC, serum levels of Ang-2 in such patients were found
to be significantly higher than in healthy individuals. It seems
likely, therefore, that serum Ang-2 levels reflect the level of Ang-2
expression in the tumour stromal compartment.
Elevated serum concentrations of Ang-2 have also been reported
for patients with cancers other than CRC, such as non-small-cell
lung cancer and melanoma, in which high serum Ang-2 levels
correlate with disease stage and poor OS (Park et al, 2007; Helfrich
et al, 2009). However, the relationship between serum Ang-2 levels
and clinical outcome in patients treated with VEGF-targeting drugs
and chemotherapeutic agents has not been explored before, and
this study is the first to investigate the impact of pre-therapeutic
serum Ang-2 concentrations on the clinical outcome in patients
with metastatic CRC under bevacizumab-containing therapy.
Compared with high serum Ang-2 levels, low serum Ang-2 was
associated with an outstanding response rate (480%), better
disease control and excellent OS (490% after 18 months). In
accordance with previous reports (Jubb et al, 2006a), VEGF and
tumour MVD were not similarly correlated to these end points.
Similarly, the pericyte content of CRC was not linked to treatment
outcome and did not correlate with Ang-2 serum concentrations,
indicating that serum Ang-2 is probably not simply a surrogate of
blood vessel morphology.
On the basis of experimental models, Ang-2 has been described
as an opponent of vascular normalisation that prevents blood
vessels from becoming structurally and functionally stabilised
(Maisonpierre et al, 1997; Scharpfenecker et al, 2005; Falcon et al,
2009; Reiss et al, 2009). Conceivably, normalisation of tumour
vessels by bevacizumab-mediated blockade of VEGF may be more
difficult to achieve and chemotherapeutic drugs cannot be
delivered appropriately to the tumour cells when Ang-2 serum
levels are high. From a mechanistic point of view, the observation
that patients with low serum Ang-2 were most likely to benefit
from treatment with respect to major clinical end points supports
such a biological role of Ang-2. From a clinical perspective, our
observations suggest that serum Ang-2 could hold promise as a
predictive biomarker allowing bevacizumab-containing treatment
to be customised in CRC patients.
Having analysed a heterogeneous patient cohort of moderate
size, our study is not without limitations. Nevertheless, subgroup
analyses of known prognostic factors in CRC (for example, age,
ECOG) showed no evidence that outcome by Ang-2 was biased by
those factors. The major and novel finding of this study is that pre-
therapeutic serum Ang-2 not only predicted OS in the study
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response rate), suggesting that Ang-2 is a stromal determinant of
both resistance and response to bevacizumab-containing therapy.
As this is a single-arm study, it remains undecided whether serum
Ang-2 is a specific outcome predictor for bevacizumab or
chemotherapy or for the combination of both. Irrespective of its
specific predictive properties, however, measurements of pre-
therapeutic serum Ang-2 could be valuable. For example, CRC
patients awaiting secondary resection of metastases could be
stratified by serum Ang-2 levels into risk groups. Whereas patients
with low serum Ang-2 are likely to benefit from neoadjuvant
bevacizumab-containing treatment, patients with high serum
Ang-2 could require escalation of chemotherapy or use of other
biologicals such as EGFR antibodies in patients with wild type
k-ras oncogene or Ang-2 inhibitors that are currently in clinical
development (Hu and Cheng, 2009). Although definitive judge-
ment on the role of Ang-2 as a specific biomarker of outcome to
bevacizumab in CRC or other cancers will require analysis of large
numbers of blood samples from phase III clinical trials comparing
bevacizumab-containing therapy with chemotherapy alone, the
promising results of this study should encourage researchers
to further investigate the predictive value of Ang-2 in cancer
treatment.
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